Introduction: The impact of hyperhidrosis on quality of life is comparable to, or greater than, psoriasis or eczema. Glycopyrronium tosylate (GT; formerly DRM04) is a cholinergic receptor antagonist developed for topical application for the treatment of primary axillary hyperhidrosis. ATMOS-1 (NCT02530281) and ATMOS-2 (NCT02530294) were designed to assess the efficacy and safety of GT in patients with primary axillary hyperhidrosis.
Σάββατο 18 Αυγούστου 2018
Topical glycopyrronium tosylate (DRM04) for the treatment of primary axillary hyperhidrosis: Pooled results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Small molecule inhibitor of the Wnt pathway (SM04755) as a potential topical treatment for psoriasisBackground: Psoriasis (PSO) is an autoimmune disease causing patches of thick, inflamed, scaly skin due to excessive proliferation of skin c...
-
Clinical and animal studies show that ethanol exposure and inflammation during pregnancy cause similar behavioral disturbances in the offspr...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.